---
title: "Top Pharvaris Executive Cashes In on Major Insider Stock Sale"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299385667.md"
description: "Pharvaris (PHVS) executive Stefan Andreas Abele sold 46,400 shares for $1.77M on Sept 17, 2026. The sale coincides with rising stock prices driven by positive Phase 3 data for hereditary angioedema treatment and raised analyst price targets. Despite strong technical momentum and a neutral AI rating, the company faces weak financials with no revenue and widening losses."
datetime: "2026-09-18T02:05:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299385667.md)
  - [en](https://longbridge.com/en/news/299385667.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299385667.md)
generator: "portal-rs"
---

# Top Pharvaris Executive Cashes In on Major Insider Stock Sale

New insider activity at Pharvaris ( (PHVS) ) has taken place on September 17, 2026.

Chief Technical Operations Officer Stefan Andreas Abele has offloaded 46,400 shares of Pharvaris stock in a recent transaction, generating total proceeds of $1,770,786. This sizable sale by a senior executive highlights notable insider activity at the company and may attract attention from investors monitoring leadership’s trading decisions.

Pharvaris shares moved higher as multiple firms raised price targets following strong CHAPTER-3 Phase 3 data for oral deucrictibant XR in hereditary angioedema. Analysts highlighted “injectable-like” efficacy, an 83% reduction in monthly attack rates versus placebo, clean overall safety despite two liver enzyme cases, and efficacy comparable to Takhzyro, boosting confidence in commercial potential and success probability.

**Spark’s Take on PHVS Stock**

According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.

Overall score is held back primarily by weak financial performance (no revenue, widening losses, and heavy cash burn), partially offset by a strong low-debt balance sheet. Technical conditions are currently favorable with the price in an uptrend and positive momentum, but valuation remains challenging due to negative earnings and no dividend.

To see Spark’s full report on PHVS stock,  
 click here. 

**More about Pharvaris**

**YTD Price Performance:** 35.32%

**Average Trading Volume:** 708,401

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $2.66B

### Related Stocks

- [PHVS.US](https://longbridge.com/en/quote/PHVS.US.md)

## Related News & Research

- [Pharvaris Presents Phase 3 Deucrictibant Data at ACAAI Annual Scientific Meeting](https://longbridge.com/en/news/303549251.md)
- [Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade](https://longbridge.com/en/news/302917214.md)
- [Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $395,575.45 in Stock](https://longbridge.com/en/news/300158569.md)
- [Morgan Stanley Reaffirms Their Buy Rating on Pharvaris (PHVS)](https://longbridge.com/en/news/299653667.md)
- [Can SpaceX Overcome the AI Trade Sell-Off?](https://longbridge.com/en/news/303907541.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**